📊 Did you know? SLD affects an estimated 1.7 billion people worldwide, making it the fastest-growing cause of chronic liver disease globally.
🔗Read our position statement: https://ow.ly/Kk2Z50ZPcjB
#LiverHealth #SteatoticLiverDisease #NCDs

📊 Did you know? SLD affects an estimated 1.7 billion people worldwide, making it the fastest-growing cause of chronic liver disease globally.
🔗Read our position statement: https://ow.ly/Kk2Z50ZPcjB
#LiverHealth #SteatoticLiverDisease #NCDs
📋 Revisiting our joint position statement on steatotic liver disease (SLD).
Endorsed by 50+ global partners, calling for SLD to be recognised within NCD strategies: https://ow.ly/IhfP50ZPcgx
#LiverHealth #SteatoticLiverDisease #NCDs
In more than 850 000 adults with #SteatoticLiverDisease, the steatosis-associated fibrosis estimator (SAFE) score provided the greatest net benefit for identifying 10-year cirrhosis risk and may help guide repeat surveillance. ja.ma/4xGTuBh
We hope you'll be at the 2026 CASL Single Topic Conference on Steatotic Liver Disease in Montreal, September 18-19. Looking forward to connecting with the Canadian liver health community.
Learn more: caslstc.ca